NCT06333509View on ClinicalTrials.gov

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

June 15, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple MyelomaPrimary Plasma Cell Leukemia
Interventions
BIOLOGICAL

CT071

a single CAR-T infusion of CT071

Sponsors
All Listed Sponsors
lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY